The interferon treatment for hematologic neoplasms.

概要

論文の詳細を見る
Clinical trials conducted in large series of patients with hematologic neoplasms have confirmed the antitumor activity of interferon alpha (α-IFN). So far, the most impressive response have occurred in patients with hairy cell leukemia, chronic myelogenous leukemia and multiple myeloma.For hairy cell leukemia, response rate of α-IFN was 37% to 100%, recently α-IFN has been used usually with small dose (2-3 mega U/body) and continued for a long time (more than 6 months). For chronic myelogenous leukemia in good phase, response rate of α-IFN was 68% to 96, and it was reported that Ph1 cells disappeared in some patients treated with α-IFN. For multiple myeloma, response rate of α-IFN was about 20%, recently α-IFN has been used for the treatment combined with chemotherapy and for maintenance therapy.In Japan, clinical trials of interferon should- be tested for many patients with hematologic malignancies.
一般社団法人国立医療学会の論文